Seladelpar

Seladelpar
Clinical data
Pronunciation/ˌsɛləˈdɛlpɑːr/
SEL-ə-DEL-par
Trade namesLivdelzi, others
Other namesMBX-8025; RWJ-800025
AHFS/Drugs.comMonograph
MedlinePlusa624062
License data
Routes of
administration
By mouth
ATC code
Legal status
Legal status
Identifiers
  • 2-[4-[(2R)-2-ethoxy-3-[4-(trifluoromethyl)phenoxy]propyl]sulfanyl-2-methylphenoxy]acetic acid
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC21H23F3O5S
Molar mass444.47 g·mol−1
3D model (JSmol)
  • CCO[C@H](COC1=CC=C(C=C1)C(F)(F)F)CSC2=CC(=C(C=C2)OCC(=O)O)C
  • InChI=1S/C21H23F3O5S/c1-3-27-17(11-28-16-6-4-15(5-7-16)21(22,23)24)13-30-18-8-9-19(14(2)10-18)29-12-20(25)26/h4-10,17H,3,11-13H2,1-2H3,(H,25,26)/t17-/m1/s1
  • Key:JWHYSEDOYMYMNM-QGZVFWFLSA-N

Seladelpar, sold under the brand name Livdelzi, is a medication used for the treatment of primary biliary cholangitis. It is used as the lysine dihydrate salt. It is a peroxisome proliferator-activated receptor delta (PPARδ) receptor agonist. The compound was licensed from Janssen Pharmaceutica NV.

Seladelpar was approved for medical use in the United States in August 2024.